Rhizome AI Launches: Know What The FDA Thinks
Rhizome AI recently launched!
"Instantly answer regulatory questions with up to 1,000 documents from public health authority databases without hallucinations."
TL;DR What has the FDA’s feedback been on real world evidence in review comments? Rhizome AI helps life science companies know what the FDA thinks.
Regulatory affairs teams ask a question and get an answer backed by terabytes of regulatory & clinical databases from the US, EU, etc.
Unlike ChatGPT, Rhizome reads up to 1,000 documents per question, accompanies each statement with a citation, and doesn’t hallucinate.
Founded by Chetan Mishra
Hi everyone, meet Chetan, the founder of Rhizome AI.
Ask: If you know any biotech or medtech leaders (esp. if they’re regulatory affairs or R&D), Chetan would appreciate an intro!
Ultimately Chetan wants all reg affairs teams to be as informed as the most regulatory man in the world.
🤝 Who The Founder Is
A bit about Chetan's background. He joined EvolutionaryScale as their first product engineer, launching an AI inference platform to help scientists design proteins. He joined Instabase as #16 helping banks with document & imaging processing, closing $7m as the technical lead. When looking to start his own company, Chetan realized there are many AI startups focused on drug discovery, but a lot less attention bringing those products to market.
😖 The Problem: Knowing What The FDA Thinks
The FDA is the customer of every function in life sciences. It doesn’t matter whether you are regulatory affairs, R&D, quality, manufacturing, commercial, etc.
At the same time, it’s difficult to understand their thinking. Guidance documents are high level and vague. The only alternative is doing (or paying a consultant to do) manual, painful research on past decisions they’ve made and understand why. Other regulators around the globe are no easier.
ChatGPT / Claude / etc. have only made it worse:
- They trust their knowledge and only look up what they feel the need to. This means low-latency, but high-hallucination research.
- Even when they retrieve sources, at most, it’s a few dozen. It’s also liable to include lots of internet junk mixed in with the authoritative government databases the industry trusts.
- They don’t make it easy to check citations. They cite a 1200 page PDF and you don’t really know where to dig inside it.
✨ The Solution: Hallucination-Free, Deep Research For Life Sciences
Rhizome solves this problem by providing hallucination-free and thorough deep research for the life sciences. There’s a few key things their customers like:
- Rhizome didn’t have a single hallucination reported in 2025.
- Every statement comes with a citation.
- Rhizome reads up to 1,000 documents per question in a few minutes before writing an answer. They’re continuously extending this limit.
Here’s a quick peek at the product:
Rhizome customers love it. A few testimonials:
- “Last time we did this research, we spent weeks. Rhizome found the answer immediately.” - a VP of reg affairs at a clinical-stage biotech.
- “Chetan idk what kind of magic you all did here, it’s so good.” - a VP of reg affairs at a biotech with multiple products on the market.
- “I would cry if I lost access to Rhizome.” - an RA manager at a drug delivery device company.
- “10 minutes of work can accomplish what would have taken weeks.”- a device engineer at a pharma company.
Learn More
🌐 Visit rhizomeai.com to learn more.
🙏 The Ask: Connections with regulatory affairs, quality, or R&D leaders in life sciences.
🤝 Do you know any regulatory affairs, quality, or R&D leaders in life sciences? It would be awesome to chat with them!
📣 Share this post with your friends / family in life sciences!
👣 Follow Rhizome AI on LinkedIn.
Need help with the upcoming tax deadline?
Take the stress out of bookkeeping, taxes, and tax credits with Fondo’s all-in-one accounting platform built for startups. Start saving time and money with our expert-backed solutions.
.png)
.png)
.png)
.png)
.png)











.png)

